🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

    Bioprojet Pharma

    Narcolepsy, Narcolepsy with cataplexy

    phase 1 other active

    1 trial

  2. Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

    Bioprojet Pharma

    Binge eating disorder

    phase 1 other active

    1 trial

  3. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  4. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  5. Oral Fosmanogepix

    Basilea Pharmaceutica

    Healthy

    phase 1 small molecule completed

    1 trial

  6. Oxcarbazepine

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  7. Oxycodone (OxyNorm®) Injection

    Mundipharma Pty Limited

    Pain

    phase 1 small molecule completed

    1 trial

  8. Oxycodone IN

    BRIGHT MINDS BIOSCIENCES INC.

    Physiologically Based Pharmacokinetic

    phase 1 small molecule completed

    1 trial

  9. PARP inhibitor BMN-673

    BioMarin Pharmaceutical Australia Pty Ltd

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  10. PC14586

    PMV Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  11. PCS499

    Processa Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  12. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  13. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  14. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  15. PEGylated recombinant candida urate oxidase

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  16. PENNVAX-B

    INOVIO PHARMACEUTICALS, INC.

    HIV-1 Infection

    phase 1 mab completed

    1 trial

  17. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  18. PF-05280602

    CATALYST PHARMACEUTICALS, INC.

    Hemophilia A

    phase 1 mab completed

    1 trial

  19. PF614 capsule

    Ensysce Biosciences

    Pharmacokinetics

    phase 1 small molecule active

    1 trial

  20. PF614 solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  21. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

  22. PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

    Zealand Pharma A/S

    Healthy / hepatic impaired volunteers only study to assess PK parameters

    phase 1 other active

    1 trial

  23. PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

    Lacuna Pharma Pty Ltd

    relapsed/refractory hematologic malignancies

    phase 1 other active

    1 trial

  24. PRA

    CNS Pharmaceuticals

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources